Quintrio
Home

Stock overview

ProQR Therapeutics N.V. Ordinary Shares

PRQR

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Last trade $1.15
Day change -$0.03 (-2.54%)
Day range $1.13 – $1.23
Volume 949,722
Market cap $167M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for PRQR.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for PRQR.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

ProQR Therapeutics announced upcoming presentations of its Axiomer RNA editing platform at major conferences including TIDES Europe, AASLD The Liver Meeting 2026, and Nature Conferences RNA at the Bench and Bedside V. The company will showcase clinical data from its Phase 1 AX-0810 study demonstrating favorable safety and target engagement, as well as preclinical data for next-generation candidate AX-0811, with initial Phase 1 data expected in early January 2027.

GlobeNewswire Inc.

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of pharmaceutical leadership experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck. The nomination will be submitted for shareholder approval at the upcoming Annual General Meeting.

GlobeNewswire Inc.

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

ProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated CTA filings and clinical data readouts expected through 2027. ProQR expects to deliver multiple clinical data readouts within its current cash runway extending into mid-2027.

GlobeNewswire Inc.

ProQR Announces Year End 2025 Operating and Financial Results

ProQR Therapeutics reported €92.4 million in cash at year-end 2025 and advanced its lead program AX-0810 into Phase 1 testing for cholestatic diseases, with target engagement data expected in H1 2026. The company selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, achieved $4.5 million in Eli Lilly collaboration milestones, and projects cash runway into mid-2027. R&D costs increased to €44.7 million and net loss widened to €42.2 million for 2025.

GlobeNewswire Inc.

ProQR to Participate in 8th Annual Evercore Healthcare Conference

ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.